Ketoconazole, amphotericin B, and amphotericin B methyl ester: comparative in vitro and in vivo toxicological effects on neutrophil function.

Antimicrobial Agents and Chemotherapy
D J MarmerR W Steele


We investigated a number of parameters for host defense after the in vitro addition of the antifungal agents ketoconazole, amphotericin B (AMB), and amphotericin B methyl ester (AME). Similar assays were repeated before and after patients received the former two drugs. Viability by trypan blue exclusion, adherence by nylon wool columns, chemotaxis by the under-agarose technique, phagocytosis and killing by chemiluminescence, colony counts, and acridine orange direct visualization were assayed. In striking contrast to AMB and AME, ketoconazole demonstrated no significant effect on neutrophils. Adherence in the presence of therapeutic plasma levels of AMB and AME was decreased (P less than or equal to 0.005) at low drug concentrations, whereas at higher concentrations, adherence was increased (P less than 0.001). The chemotactic responses of cells incubated with AMB and AME demonstrated marked suppression. Phagocytic capacity and killing were decreased (P less than or equal to 0.005) with AMB as compared with control assays and assays performed in the presence of ketoconazole and AME. However, no difference were observed between two patients who received AMB and two other treated with ketoconazole.


Jan 1, 1978·Journal of Immunological Methods·W Orr, P A Ward
Jan 1, 1977·Antimicrobial Agents and Chemotherapy·S H LinG S Kobayashi
Apr 1, 1977·Antimicrobial Agents and Chemotherapy·A Forsgren, D Schmeling
Aug 1, 1977·Antimicrobial Agents and Chemotherapy·C J ChunnD N Gilbert
Oct 1, 1976·The Journal of Surgical Research·J A Majeski, J W Alexander
Jan 11, 1976·The Journal of Clinical Investigation·R W SteeleL O Gentry
Feb 1, 1976·The Journal of Infectious Diseases·R M Lawrence, P D Hoeprich
Apr 1, 1973·Annals of Internal Medicine·R A ClarkC H Kirkpatrick
Oct 1, 1974·The Journal of Infectious Diseases·A ForsgrenP G Quie
Feb 1, 1974·The Journal of Infectious Diseases·R R MartinV Knight
Sep 26, 1974·The New England Journal of Medicine·R R MacGregorA L Lentnek
Jun 1, 1966·Journal of Chronic Diseases·G P Bodey
Jun 1, 1970·Applied Microbiology·B T FieldsR S Abernathy
Jun 1, 1980·Antimicrobial Agents and Chemotherapy·H Van den BosscheJ M van Cutsem
Jan 17, 1980·The New England Journal of Medicine·G Medoff, G S Kobayashi

❮ Previous
Next ❯


Apr 7, 1995·Atherosclerosis·M I DushkinN N Volsky
Jan 1, 1987·Transactions of the Royal Society of Tropical Medicine and Hygiene·M A Yousif, R J Hay
Jan 1, 1990·International Journal of Immunopharmacology·V VuddhakulY H Thong
Jul 9, 2003·Critical Care Medicine·Sydney JacobsNasser Fawzan Al Omar
Apr 1, 1986·Antimicrobial Agents and Chemotherapy·G K AbruzzoR A Fromtling
Feb 1, 1990·Antimicrobial Agents and Chemotherapy·E RoilidesP A Pizzo
May 1, 1991·Antimicrobial Agents and Chemotherapy·E WilsonD P Speert
Feb 1, 1992·Antimicrobial Agents and Chemotherapy·G W SullivanG L Mandell
Jun 23, 1993·Annals of the New York Academy of Sciences·H YamaguchiY Tokuda
Jul 1, 1985·Journal of the American Academy of Dermatology·J L Lesher, D K Chalker
May 1, 1982·The American Journal of Medicine·W E Hauser, J S Remington
May 1, 1991·The American Journal of Medicine·W A SchwartzmanM B Goetz
Nov 19, 1989·Molecular and Cellular Biochemistry·N Henry-ToulméJ Bolard

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.